Visit the Canopy Growth Corp Investor Dashboard and stay up to date with data-driven, fact based due diligence for active traders and investors.
SMITHS FALLS, ON, Oct. 9, 2018 /PRNewswire/ – Marking a major milestone in cannabis history, Canopy Growth Corporation (TSX: WEED) (NYSE: CGC) (“Canopy Growth” or the “Company”) has completed a legal transfer of cannabis products to a research partner in the United States. To the Company’s knowledge, this transfer is the first export of legal cannabis products from Canada to the United States pursuant to an import permit issued by the federal United States Drug Enforcement Administration (DEA). The shipment was completed for the sole purpose of supporting medical research and development.
Currently, sources of federally regulated cannabis in the United States are limited in scope and genetic diversity. Canopy Growth believes that it can add value to the market and enable the development of rigorous testing standards for products, while advancing the understanding of the risks and benefits of medical cannabis. The advancement of this research stands to serve Americans, Canadians and those around the world who may benefit from legal, approved cannabis based medical treatments.
While this export is a major achievement for the Company, in keeping with its philosophy around the globe, Canopy Growth strongly supports legal production at the domestic level over ongoing exports. With this in mind, the Company is excited at the potential of bringing its commitment to legal, GMP/GPP produced cannabis operations to the United States but only through federally legal means.
The United States presents a unique market opportunity and as the most established cannabis business in the world we, in turn, offer a unique ability to advance standardization, IP development, and clinical research that can improve the understanding and legal application of cannabis and cannabinoids.
Mark Zekulin, President and Co-CEO, Canopy Growth
By engaging in the market through federally legal means and with the right partners, we can create a US-based centre of expertise while also supporting our rapidly expanding global business.
Canopy Growth and its subsidiaries Canopy Health Innovations (CHI) and Spectrum Cannabis have developed a strong research program spanning human and animal health. Today’s announcement builds onto our continued commitment to IP development and subsequent commercialization of cannabis-based medicines through clinical research.
Here’s to Future Growth (through research).
About Canopy Growth Corporation
Canopy Growth is a world-leading diversified cannabis and hemp company, offering distinct brands and curated cannabis varieties in dried, oil and Softgel capsule forms. From product and process innovation to market execution, Canopy Growth is driven by a passion for leadership and a commitment to building a world-class cannabis company one product, site and country at a time.
The Company has operations in 12 countries across five continents. The Company is proudly dedicated to educating healthcare practitioners, conducting robust clinical research, and furthering the public’s understanding of cannabis, and through its partly owned subsidiary, Canopy Health Innovations, has devoted millions of dollars toward cutting edge, commercializable research and IP development. Through partly owned subsidiary Canopy Rivers Corporation, the Company is providing resources and investment to new market entrants and building a portfolio of stable investments in the sector.
From our historic public listing on the Toronto Stock Exchange and New York Stock Exchange to our continued international expansion, pride in advancing shareholder value through leadership is engrained in all we do at Canopy Growth. Canopy Growth has established partnerships with leading sector names including cannabis icon Snoop Dogg, breeding legends DNA Genetics and Green House seeds, and Fortune 500 alcohol leader Constellation Brands, to name but a few. Canopy Growth operates ten licensed cannabis production sites with over 4.3 million square feet of production capacity, including over 500,000 square feet of GMP certified production space. For more information visit www.canopygrowth.com.
The most reliable, fact-based information on Canopy Growth Corp. found only on its Investor Dashboard.
Before this cannabis stock news is here, it’s published to subscribers on 420 Investor.